Radiotherapy (radiation treatment) is often used to treat lung cancers and lung tumors that have spread from other cancers. It can be very effective, especially in early-stage lung cancer or when there are only a few tumor sites. Even so, some patients later develop a local recurrence, meaning the cancer comes back in the same area that was previously treated with radiation. When this happens, treatment options are limited. Surgery can sometimes remove the recurrent tumor, but many patients are not able to have surgery because of their general health or because the tumor is difficult to remove. For these patients, a second course of radiotherapy (called re-irradiation) may be the only possible treatment. One type of radiotherapy, called stereotactic body radiotherapy (SBRT), delivers very high doses of radiation very precisely. SBRT has been used successfully as a second treatment after standard radiotherapy in some patients. However, there is very little information about using SBRT again in patients who already received SBRT the first time. Because only small studies have been done and the patients were very different from each other, doctors still do not know enough about how safe and effective a second SBRT treatment is. In particular, it is still unclear whether giving another high-dose radiation treatment is possible without causing serious side effects. More research is needed to better understand this option and help guide treatment decisions for patients.
Study Type
OBSERVATIONAL
Enrollment
150
AST Papa Giovanni XXIII
Bergamo, Bergamo, Italy
RECRUITINGRadiotherapy Department, Ospedale Bellaria Carlo Alberto Pizzardi
Bologna, Bologna, Italy
NOT_YET_RECRUITINGREM Radioterapia
Catania, Catania, Italy
NOT_YET_RECRUITINGRadiation oncology unit, Ospedale San Raffaele
Milan, Milano, Italy
NOT_YET_RECRUITINGRadiotherapy Department, Istituto Europeo di Oncologia
Milan, Milano, Italy
NOT_YET_RECRUITINGIRCCS Humanitas Research Hospital
Rozzano, Milano, Italy
RECRUITINGRadiotherapy Department, IRCCS Istituto Nazionale Fondazione G. Pascale
Naples, Napoli, Italy
NOT_YET_RECRUITINGCentro Fondazione Policlinico Universitario "A. Gemelli", Radioterapia Oncologica
Roma, Roma, Italy
NOT_YET_RECRUITINGRadioterapia Oncologica - Ospedale dell'Angelo
Venezia, Venezia, Italy
NOT_YET_RECRUITINGAdvanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Cancer Care Center
Negrar, Verona, Italy
NOT_YET_RECRUITING...and 1 more locations
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
evaluation of treatment safety through toxicities according to the CACTE scale
Time frame: from treatment to 1 years follow up
Number of partecipant with local control
defined as the absence of progression within the field of SABR, assessed by contrast-enhanced CT scan
Time frame: from enrollment to 1 years follow up
Time to new systemic treatment
time from the first day of SBRT to change or starting of new systemic therapies
Time frame: from enrollment to 1 years follow up
Progression free survival
time from the first day of SABR until the date of detection of progressive disease (in-field or out-field) or death, whichever occurred first.
Time frame: from enrollment to 1 years follow up
Overall survival
time from the first day of SABR to death. Patients lost to follow-up have their OS censored at the last date they were known to be alive
Time frame: from enrollment to 1 years follow up
Dosimetric parameters related to treatment toxicity
analysis between correlation between treatment dosage and occurrence of toxicity
Time frame: from enrollment to 1 years follow up
Davide Franceschini, MD, radiation oncologist
CONTACT
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.